Your partnership to FARE matters more and more as food allergy has become a prominent health issue in America. As the leading national advocacy organization working on behalf of the 15 million Americans who have food allergies, FARE strives to provide a national voice to ensure individuals and families with food allergies live safe, productive… Continue reading Your Donations at Work in 2016
My name is Daytona. I am allergic to peanuts. I’ve had symptoms of food allergies since I was born. When I was 10 months old, a friend gave me a cookie to chew on. My lips began to swell, my ears turned fire engine red, my cheeks puffed up and my eyes bulged. For my… Continue reading This is Daytona: A Food Allergy Role Model
This year’s 11th Annual Teen Summit introduced a few “FARE firsts.” First time in the Midwest. First time with an Ask-the-Experts Hour. And the first ever FARE Innovation Tank, which gave teens from across the nation a chance to pitch their big idea for how to address a problem faced by the food allergy community.… Continue reading Great Ideas Take the Stage at FARE Teen Summit Innovation Tank
The Dec. 7, 2016 webinar, Epi First. Epi Fast. Ask Questions Later, featured Dr. Scott Russell, Division Chief and Medical Director of Pediatric Emergency Medicine at the Medical University of South Carolina. Dr. Russell opened with anaphylaxis definitions from several sources before recommending a “gut check” definition for parents, noting that anaphylaxis symptoms can affect almost any… Continue reading Webinar Recording and Recap: Epi First. Epi Fast. Ask Questions Later.
My name is Melody. My son, Noah, has both anaphylaxis-mediated allergies and eosinophilia esophagitis (EoE). Noah is “labeled” all the time. Despite all of it, everyone always says, “But he’s so happy!” They don’t believe that he can have allergies AND be happy. Labeling even happens to me. When people hear about Noah, they automatically… Continue reading This is Noah: Food Allergy “Happy” Kid
A blinded, controlled study on the use of omalizumab (Xolair) in oral immunotherapy for peanut allergy is currently in press at the Journal of Allergy and Clinical Immunology. Funded largely by FARE, the multi-center Phase 2 trial PRROTECT (Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial) tested whether the drug could improve… Continue reading Omalizumab (Xolair) Facilitates Rapid Oral Desensitization for Peanut Allergy
By Julie Wilcox Member, FARE Board of Directors After my daughter was diagnosed with food allergies, I felt a strong need to become involved within the food allergy community. When my daughter was five, I signed up for the Boston FARE Walk for Food Allergy and to my surprise, I received an email asking if… Continue reading Guest Post: Help Redefine the Future of Food Allergies by Doubling Your Impact